Samsung nets FDA clearance

Article

Samsung nets FDA clearanceKorean PACS vendor Samsung has officially entered the U.S. market, with news that its Raypax PACS product line has received Food and Drug Administration 510(k) clearance. Raypax is based on Windows NT and Windows 98

Samsung nets FDA clearance

Korean PACS vendor Samsung has officially entered the U.S. market, with news that its Raypax PACS product line has received Food and Drug Administration 510(k) clearance. Raypax is based on Windows NT and Windows 98 architecture, although its image server is also available on the Unix platform (

PNN

9/98).

Raypax comprises display software, an image server, a Web server, a film and plain paper printer server, modality interfaces, and a Web-based teleradiology system. Digitizers as well as DICOM and HL7 gateways are available. Samsung also markets a radiology information system.

Samsung, which has U.S. operations in San Jose, CA, plans to install a U.S. beta site for Raypax this month. Raypax is sold through distributors, and Asian sales of Raypax began in April. Beta testing of Raypax was performed at Samsung Medical Center in Seoul.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.